Literature DB >> 7492082

Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.

S Merali1, K Chin, R W Grady, L Weissberger, A B Clarkson.   

Abstract

The iron-chelating drug deferoxamine mesylate (DFO) is active against Pneumocystis carinii in vitro and in rat and mouse models of P. carinii pneumonia. Because DFO has a short half-life, daily divided or continuous dosage was expected to improve the dose response, as is the case with DFO treatment of malaria. Therefore, results of single daily intraperitoneal injections were compared with results of an evenly divided four-times-daily dosage and the efficacy of delivery with implanted infusion pumps. The highest bolus dosage (1,000 mg kg-1 of body weight day-1) was as effective as the standard combination of trimethoprim with sulfamethoxazole. Unexpectedly, very little improvement was observed with the divided or continuous dosage, and several mechanisms that could account for this are discussed.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7492082      PMCID： PMC162759          DOI： 10.1128/AAC.39.7.1442

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Iron chelation therapy for malaria.

Authors:  V R Gordeuk; P E Thuma; G M Brittenham
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

2.  The metabolism of desferrioxamine B and ferrioxamine B.

Authors:  H G Meyer-Brunot; H Keberle
Journal:  Biochem Pharmacol       Date:  1967-03       Impact factor: 5.858

Review 3.  Recent advances in the diagnosis, treatment, and prevention of Pneumocystis carinii pneumonia.

Authors:  R T Davey; H Masur
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

4.  Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.

Authors:  M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis.

Authors:  P Allain; Y Mauras; D Chaleil; P Simon; K S Ang; G Cam; L Le Mignon; M Simon
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

6.  Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.

Authors:  P Lee; N Mohammed; L Marshall; R D Abeysinghe; R C Hider; J B Porter; S Singh
Journal:  Drug Metab Dispos       Date:  1993 Jul-Aug       Impact factor: 3.922

7.  Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.

Authors:  A B Clarkson; M Sarić; R W Grady
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

8.  Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.

Authors:  P Allain; D Chaleil; Y Mauras; G Beaudeau; M C Varin; J L Poignet; C Ciancioni; K S Ang; G Cam; P Simon
Journal:  Clin Chim Acta       Date:  1987-12       Impact factor: 3.786

9.  Iron chelators as therapeutic agents against Pneumocystis carinii.

Authors:  G A Weinberg
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

10.  Suppressive effect of deferoxamine on the growth of Pneumocystis carinii in vitro.

Authors:  G A Weinberg; M M Shaw
Journal:  J Protozool       Date:  1991 Nov-Dec
View more
  6 in total

1.  Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.

Authors:  S Merali; K Chin; R W Grady; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.

Authors:  K Chin; S Merali; M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Continuous axenic cultivation of Pneumocystis carinii.

Authors:  S Merali; U Frevert; J H Williams; K Chin; R Bryan; A B Clarkson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Action of deferoxamine against Pneumocystis carinii.

Authors:  A B Clarkson; D Turkel-Parrella; J H Williams; L C Chen; T Gordon; S Merali
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors:  S Merali; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

6.  Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.

Authors:  S Merali; K Chin; L Del Angel; R W Grady; M Armstrong; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.